{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002100","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.023073+00:00","generated_at":"2026-06-07T01:48:25.071272+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Novavax reaffirms FY2023 combined R&D and SG&A expense guidance of $1.15-1.25B","bullets":["Reaffirmed full-year 2023 combined R&D and SG&A expenses anticipated between $1.15B and $1.25B.","Preliminary data as company finalizes 2023 financial results; Ernst & Young not audited.","Update provided at 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024.","Additional material information expected in final financial statements; caution against undue reliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002100","json":"https://secwatch.observer/filing/0001104659-24-002100.json","markdown":"https://secwatch.observer/filing/0001104659-24-002100.md","text":"https://secwatch.observer/filing/0001104659-24-002100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/0001104659-24-002100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/tm242356d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:48:25.071272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb488d8bb7253f8c6b57595fd4b85ba2e3e3e250","claim":"NOVAVAX INC updated its the year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On January 8, 2024, Novavax, Inc. (the “Company”) provided an update for investors in which it reaffirmed its guidance for full year 2023 combined research and development and selling, general and administrative expenses, which is anticipated to be between $1.15 billion and $1.25 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924002100/0001104659-24-002100-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}